Characteristics | All (N = 44) | BCOR | | | |
---|
| | Negative (N = 23) | Focal weak +ve (N = 7) | Diffuse strong +ve (N = 14) | p-value |
---|
| No. (%) | No. (%) | No. (%) | No. (%) | |
---|
Age (years) |
Mean ± SD | 56.84 ±7.93 | 62.52 ±4.98 | 51 ±7.85 | 50.42 ±4.23 | <0.001* |
Median (Range) | 57 (39-72) | 62 (56-72) | 51 (39-60) | 50 (44-60) | |
≤ 55 years | 18 (40.9%) | 0 (0%) | 5 (27.8%) | 13 (72.2%) | <0.001‡ |
> 55 years | 26 (59.1%) | 23 (88.5%) | 2 (7.7%) | 1 (3.8%) | |
Histopathology |
LMS | 22 (50%) | 19 (86.4%) | 2 (9.1%) | 1 (4.5%) | <0.001‡ |
ESS | 22 (50%) | 4 (18.2%) | 5 (22.7%) | 13 (59.1%) | |
Grade |
Grade I | 9 (20.5%) | 9 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
Grade II | 12 (27.3%) | 6 (50%) | 6 (50%) | 0 (0%) | |
Grade III | 23 (52.3%) | 8 (34.8%) | 1 (4.3%) | 14 (60.9%) | |
Extrauterine extension |
Absent | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | 0.007‡ |
Present | 9 (20.5%) | 7 (77.8%) | 2 (22.2%) | 0 (0%) | |
N/A | 29 (65.9%) | 10 (34.5%) | 5 (17.2%) | 14 (48.3%) | |
LVSI | | | | | |
Absent | 21 (47.7%) | 15 (71.4%) | 5 (23.8%) | 1 (4.8%) | 0.001‡ |
Present | 23 (52.3%) | 8 (34.8%) | 2 (8.7%) | 13 (56.5%) | |
Other pelvic organ invasion |
Absent | 15 (34.1%) | 9 (60%) | 5 (33.3%) | 1 (6.7%) | 0.010‡ |
Present | 29 (65.9%) | 14 (48.3%) | 2 (6.9%) | 13 (44.8%) | |
Adnexal invasion |
Absent | 11 (25%) | 11 (100%) | 0 (0%) | 0 (0%) | 0.001‡ |
Present | 33 (75%) | 12 (36.4%) | 7 (21.2%) | 14 (42.4%) | |
Lymph node |
Negative | 16 (36.4%) | 14 (87.5%) | 2 (12.5%) | 0 (0%) | 0.001‡ |
Positive | 28 (63.6%) | 9 (32.1%) | 5 (17.9%) | 14 (50%) | |
Distant metastasis |
Absent | 29 (65.9%) | 19 (65.5%) | 7 (24.1%) | 3 (10.3%) | <0.001‡ |
Present | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
FIGO Stage |
Stage I | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | <0.001‡ |
Stage II | 10 (22.7%) | 8 (80%) | 2 (20%) | 0 (0%) | |
Stage III | 13 (29.5%) | 5 (38.5%) | 5 (38.5%) | 3 (23.1%) | |
Stage IV | 15 (34.1%) | 4 (26.7%) | 0 (0%) | 11 (73.3%) | |
Stathmin |
Negative | 19 (43.2%) | 4 (21.1%) | 5 (26.3%) | 10 (52.6%) | 0.007‡ |
Focal weak +ve | 12 (27.3%) | 10 (83.3%) | 0 (0%) | 2 (16.7%) | |
Diffuse strong +ve | 13 (29.5%) | 9 (69.2%) | 2 (15.4%) | 2 (15.4%) | |
Transgelin |
Negative | 25 (56.8%) | 7 (28%) | 5 (20%) | 13 (52%) | 0.004‡ |
Focal weak +ve | 6 (13.6%) | 6 (100%) | 0 (0%) | 0 (0%) | |
Diffuse strong +ve | 13 (29.5%) | 10 (76.9%) | 2 (15.4%) | 1 (7.7%) | |
Cyclin-D1 |
Negative | 24 (54.5%) | 21 (87.5%) | 2 (8.3%) | 1 (4.2%) | <0.001‡ |
Focal weak +ve | 5 (11.4%) | 2 (40%) | 3 (60%) | 0 (0%) | |
Diffuse strong +ve | 15 (34.1%) | 0 (0%) | 2 (13.3%) | 13 (86.7%) | |
- * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant